Európska únia - angličtina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,

Európska únia - angličtina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - hiv infections - antivirals for systemic use - hard capsuleszerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.powder for oral solutionzerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.

Európska únia - angličtina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - carcinoma, non-small-cell lung - antineoplastic and immunomodulating agents, monoclonal antibodies - nivolumab bms is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (nsclc) after prior chemotherapy in adults.

Izrael - angličtina - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Izrael - angličtina - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.

Izrael - angličtina - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).

Izrael - angličtina - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 300 mg - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 20mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 50mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - abatacept - powder for solution for infusion - 250mg